SALES WORLDWIDE
$7.3B

SALES PERFORMANCE ACROSS ABBOTT
$2B DIASTOLOGY
$1.9B MEDICAL DEVICES
$2.4B SHIELD PHARMACEUTICALS
$1B DENTAL<br>

FULL-YEAR 2020 EPS GUIDANCE<br>at least $3.25<br>ADJUSTED DILUTED EARNINGS PER SHARE

LEADER IN GLOBAL COVID-19 TESTING
- 2 lab-based molecular tests to detect the virus
- 2 lab-based serology tests that confirm previous infections
- 40M COVID-19 TESTS SOLD WORLDWIDE

MORE TESTS IN THE PIPELINE TO HELP TEST AS MANY PEOPLE AS POSSIBLE

STRENGTH IN OUR DIVERSIFIED BUSINESS

FreeStyle Libre<br>Sales up 40%
IN D-1 PER-USER

- Abbott Diagnostics wins up COVID-19<br>test Drag Test sales up 2X in<br>supported by 200 million<br>assays<br>- Accelerate commercialization as<br>COVID-19 tests<br>- Accelerate commercialization of<br>high-throughput oligo-priming<br>diagnostic instruments
- Announced U.S. FDA clearance of FreeStyle<br>Libre 14+, an advanced continuous glucose monitoring (CGM) system for adults and<br>children age 14 and older that provides<br>longer interval between required<br>measurements with optional self-<br>monitoring
- Announced collaboration with Johnson<br>Clinical Care to expand access to its<br> HeroCardio<sup>®</sup> wearable<br>monitoring device for pulmonary<br>dysfunction delivery patients

Diagnostics<br>Sales up 7%
IN ORGANIC<sup>®</sup>

- Announced FDA premier market for<br>microchip-<br>embedded<br>therapeutics<br>- Announced 510(k) clearance for<br>glucose<br>monitoring<sup>™</sup><br>- Announced a new<sup>™</sup> diagnostic that<br>identifies the<br>source of<br>diabetes<sup>™</sup>

Secured Approvals<br>FOR IMPORTANT HEART DEVICES

"Life-changing technology rises to the test."

Abbott. Making healthcare more affordable.®